IP Library › Granted Patent US 12,263,162
Granted Patent B2
US 12,263,162 · App. 16/933,560 · Granted Apr 1, 2025

Compositions, devices, and methods for treating or preventing headaches

Inventors: John Kollins (San Francisco, CA); Fumiyoshi Iwashima (San Francisco, CA); Detlef Albrecht (Saratoga, CA); Robert David Schultz (Raleigh, NC)
Assignee: SATSUMA PHARMACEUTICALS, INC.
A61K31/4985A61K9/0019A61K9/0043A61K9/14A61K47/26A61K47/38A61M15/08A61P25/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,263,162
App. No.
16/933,560
Granted
Apr 1, 2025
Kind
B2
Abstract

Disclosed herein are pharmaceutical compositions, devices, their combinations, and their uses thereof for example in treating or preventing headaches.

Claims (26)

1. A method for treating or preventing a headache, comprising administering to a human subject a powdery pharmaceutical composition that comprises 5 mg to about 7 mg of dihydroergotamine mesylate, and an excipient;

wherein said excipient comprises about 18 mg to about 19 mg of microcrystalline cellulose, and hydroxypropyl methylcellulose.

2. The method of claim 1 , wherein the method does not cause clinically significant changes in nasal mucosa integrity, nasal irritation, or a combination thereof, wherein said clinically significant changes in nasal mucosa integrity, nasal irritation, or a combination thereof may be measured by a mean Visual Analog Scale score, wherein said mean Visual Analog Scale score is less than about 20 if measured within 24 hours following said administration, wherein said Visual Analog Scale score is measured in a scale of 0 (none) to 100 (worst imaginable) based on each of the following nasal symptoms: nasal discomfort, nasal burning, nasal itching, nasal pain, nasal blockage or obstruction, abnormal taste, runny nose, and sneezing.

3. The method of claim 2 , wherein said Visual Analog Scale score is measured at about 4 hours following said administration.

4. The method of claim 2 , wherein said Visual Analog Scale score is measured at about 1 hour following said administration.

5. The method of claim 2 , wherein said Visual Analog Scale score is measured at about 15 minutes following said administration.

6. The method of claim 2 , wherein said Visual Analog Scale score is measured at about 5 minutes following said administration.

7. The method of claim 2 , wherein said Visual Analog Scale score is less than about 10.

8. The method of claim 2 , wherein said Visual Analog Scale score is less than about 5.

9. The method of claim 2 , wherein said Visual Analog Scale score is about 0.

10. The method of claim 1 , wherein said administration comprises delivering two or more unit doses of said powdery pharmaceutical composition in two or more devices to said human subject.

11. The method of claim 10 , wherein said two or more unit doses are administered successively to said human subject.

12. The method of claim 10 , wherein said two or more unit doses are administered sequentially by about 2 hours or longer apart.

13. The method of claim 1 , wherein said administration is intranasal.

14. The method of claim 1 , wherein said headache is a migraine headache.

15. The method of claim 1 , wherein said headache comprises a migraine headache with aura, a migraine headache without aura, cluster headache, post-traumatic headache, hemiplegic migraine, basilar migraine, episodic migraine, chronic migraine, refractory migraine, migraine attack when treatment is initiated at least 1-24 hours after an onset of attack, migraine attack when treatment is initiated at the earliest premonitory sign or symptom, pediatric migraine, status migraine, chronic daily headache, a migraine attack with allodynia, menstrually-associated migraine, menstrual migraine, migraine-upon-awakening, rapid-onset migraine, or any combination thereof.

16. The method of claim 1 , wherein said administering to a human subject comprises administering two or more unit doses of the powdery pharmaceutical composition sequentially by about 1 or about 2 hours apart, in two or more devices.

17. The method of claim 16 , wherein said two or more unit doses are administered sequentially by about 2 hours apart.

18. The method of claim 16 , wherein said administration is intranasal.

19. The method of claim 16 , wherein said headache is a migraine headache.

20. The method of claim 16 , wherein said headache comprises a migraine headache with aura, a migraine headache without aura, cluster headache, post-traumatic headache, hemiplegic migraine, basilar migraine, episodic migraine, chronic migraine, refractory migraine, migraine attack when treatment is initiated at least 1-24 hours after an onset of attack, migraine attack when treatment is initiated at the earliest premonitory sign or symptom, pediatric migraine, status migraine, chronic daily headache, a migraine attack with allodynia, menstrually-associated migraine, menstrual migraine, migraine-upon-awakening, rapid-onset migraine, or any combination thereof.

21. The method of claim 16 , wherein each of said two or more devices comprises a poppet valve and a retainer, wherein the retainer is hollow and holds the poppet valve.

22. The method of claim 2 , wherein said clinically significant changes in nasal mucosa integrity, nasal irritation, or a combination thereof, is measured using an assessment conducted one or more times.

23. The method of claim 22 , wherein said assessment is an objective assessment.

24. The method of claim 22 , wherein said clinically significant changes in nasal mucosa integrity, nasal irritation, or a combination thereof, is measured by a subjective assessment.

25. The method of claim 1 , wherein the dihydroergotamine mesylate is amorphous dihydroergotamine mesylate.

Assignments (2)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Apr 17, 2025
From: SATSUMA PHARMACEUTICALS, INC.
To: SATSUMA PHARMACEUTICALS, INC.
Reel/Frame 070887/0785 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2020
From: KOLLINS, JOHN; IWASHIMA, FUMIYOSHI; ALBRECHT, DETLEF; SCHULTZ, ROBERT DAVID
To: SATSUMA PHARMACEUTICALS, INC.
Reel/Frame 053593/0110 →
Continuity (5)
Continuation 16710538 · Dec 11, 2019
Provisional Application 62847607 · May 14, 2019
Provisional Application 62799635 · Jan 31, 2019
Provisional Application 62778158 · Dec 11, 2018
Related Publication 20200345730A1 · Nov 5, 2020
References Cited (144)
US 4613500A · Suzuki et al. · 1986 [cited by applicant]
US 5169849A · Kiechel et al. · 1992 [cited by applicant]
US 5756483A · Merkus · 1998 [cited by applicant]
US 6906027B2 · Oki et al. · 2005 [cited by applicant]
US 7022311B1 · Ohkuma et al. · 2006 [cited by applicant]
US 7638138B2 · Oki et al. · 2009 [cited by applicant]
US 8062670B2 · Baran, Jr. et al. · 2011 [cited by applicant]
US 8062970B2 · Tanaka · 2011 [cited by applicant]
US 8435554B2 · Oki et al. · 2013 [cited by applicant]
US 8673360B2 · Nagata et al. · 2014 [cited by applicant]
US 8710092B2 · Zhang et al. · 2014 [cited by applicant]
US 8827946B2 · Tsutsui et al. · 2014 [cited by applicant]
US 9101539B2 · Nagata et al. · 2015 [cited by applicant]
US 9138410B2 · Oki et al. · 2015 [cited by applicant]
US 9707226B2 · Keegan et al. · 2017 [cited by applicant]
US 10195139B2 · Nagata et al. · 2019 [cited by applicant]
US 10758532B2 · Kollins et al. · 2020 [cited by applicant]
US 10792253B2 · Haruta · 2020 [cited by applicant]
US 20030044458A1 · Wright et al. · 2003 [cited by applicant]
US 20050118272A1 · Besse et al. · 2005 [cited by applicant]
US 20050158250A1 · Oki et al. · 2005 [cited by applicant]
US 20060057213A1 · Larhrib et al. · 2006 [cited by applicant]
US 20060147388A1 · Merkus et al. · 2006 [cited by applicant]
US 20070253913A1 · Mohsen et al. · 2007 [cited by applicant]
US 20080260848A1 · Nagata et al. · 2008 [cited by applicant]
US 20080287451A1 · Cook et al. · 2008 [cited by applicant]
US 20090163604A1 · Kakizawa et al. · 2009 [cited by applicant]
US 20090217928A1 · Patton et al. · 2009 [cited by applicant]
US 20100178331A1 · Nagata et al. · 2010 [cited by applicant]
US 20110045088A1 · Tsutsui et al. · 2011 [cited by applicant]
US 20110082150A1 · Cook et al. · 2011 [cited by applicant]
US 20110171141A1 · Kellerman et al. · 2011 [cited by applicant]
US 20110318277A1 · Dalby et al. · 2011 [cited by applicant]
US 20130095145A1 · Nagata et al. · 2013 [cited by applicant]
US 20130129781A1 · Nagata et al. · 2013 [cited by applicant]
US 20130178465A1 · Henwood et al. · 2013 [cited by applicant]
US 20140014104A1 · Hoekman et al. · 2014 [cited by applicant]
US 20140179704A1 · Kellerman et al. · 2014 [cited by applicant]
US 20140179705A1 · Armer et al. · 2014 [cited by applicant]
US 20150238412A1 · Kellerman et al. · 2015 [cited by applicant]
US 20160228433A1 · Haruta et al. · 2016 [cited by applicant]
US 20180036247A1 · Haruta · 2018 [cited by applicant]
US 20190000753A1 · Narasimha Murthy et al. · 2019 [cited by applicant]
US 20190091424A1 · Haruta · 2019 [cited by applicant]
US 20190209463A1 · Hoekman et al. · 2019 [cited by applicant]
US 20190275036A1 · Haruta et al. · 2019 [cited by applicant]
US 20200179379A1 · Haruta et al. · 2020 [cited by applicant]
US 20240108619A1 · Haruta et al. · 2024 [cited by applicant]
CN 101677954A · 2010 [cited by applicant]
GB 1592563A · 1981 [cited by applicant]
JP H1059841A · 1998 [cited by applicant]
JP 2003206227A · 2003 [cited by applicant]
JP 2005520799A · 2005 [cited by applicant]
JP 2006519219A · 2006 [cited by applicant]
JP 4721212B2 · 2011 [cited by applicant]
JP 2013126989A · 2013 [cited by applicant]
JP 2018076305A · 2018 [cited by applicant]
WO WO9422445A2 · 1994 [cited by applicant]
WO WO0027373A1 · 2000 [cited by applicant]
WO WO2004073729A1 · 2004 [cited by applicant]
WO WO2006016530A1 · 2006 [cited by applicant]
WO WO2008097664A1 · 2008 [cited by applicant]
WO WO2012105236A1 · 2012 [cited by applicant]
WO WO2012119153A2 · 2012 [cited by applicant]
WO WO2015044782A2 · 2015 [cited by applicant]
WO WO2018025089A2 · 2018 [cited by applicant]
WO WO2019065673A1 · 2019 [cited by applicant]
WO WO2019136291A1 · 2019 [cited by applicant]
WO WO2020123607A1 · 2020 [cited by applicant]
Gavezzotti Acc. Chem Res. 1994, 27, 309-314 (Year: 1994). [cited by examiner]
Gallager Arch Neurol, 1996, 53(12), 1285-1291; abstract (Year: 1996). [cited by examiner]
Van Gerven et al., (J. Allergy Clin. Immunol, 2017, 140(2), 437-446 (Year: 2017). [cited by examiner]
Anjilvel, et al. A multiple-path model of particle deposition in the rat lung. Fundamental and Applied Toxicology 28.1 (1995): 41-50. [cited by applicant]
Aurora SK, “OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program”, Headache. Oct. 2011;51(9):1358-73. doi: 10.1111/j.1526-4610.2011.01990.x. Epub Aug. 29, 2011. [cited by applicant]
Berge, et al. Pharmaceutical salts. J Pharm Sci. Jan. 1977;66(1):1-19. [cited by applicant]
CeolusTM basic information (Asahi Kasei's web site for pharmaceutical excipients), Obtained online on Sep. 17, 2015. [cited by applicant]
Detlef Albrecht et al., Pharmacokinetics and Safety of Intranasal Dihydroergotamine Powder (STS101), American Headache Society 61st Annual Scientific Meeting, Jul. 11-14, 2019, Philadelphia, PA. [cited by applicant]
Edwards KR et al., “Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache”, Headache. Nov.-Dec. 2001;41(10):976-80. [cited by applicant]
Fasiolo, Laura Tiozzo et al., “Opportunity and challenges of nasal powders: Drug formulation and delivery”, European Journal of Pharmaceutical Sciences, 2017, 1-16. [cited by applicant]
Fumiyoshi Iwashima et al., “STS101 (Dry Powder Intranasal Dihydroergotamine) Drug-Device Combination Achieves Consistent and Robust Delivery Performance for Migraine Patients”, presented at the International headache Co… [cited by applicant]
Gallagher, R. Michael, “Acute Treatment of Migraine With Dihydroergotamine Nasal Spray”, Arch Neurol 1996;53:1285-1291. [cited by applicant]
Humbert H et al., “Human pharmacokinetics of dihydroergotamine administered by nasal spray”, Clin Pharmacol Ther. Sep. 1996;60(3):265-75. [cited by applicant]
International search report and written opinion dated Mar. 20, 2015 for PCT/IB2014/002706. [cited by applicant]
International Search Report and Written Opinion dated Apr. 8, 2020 for International Application Serial No. PCT/US2019/065647. [cited by applicant]
J. N. J. M. de Hoon et al., “Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data”, J. Clin Pharmacol, 2001, 52, 45-51. [cited by applicant]
Kellerman, Donald J. et al., “Assessment of the Consistency of Absorption of Dihydroergotamine Following Oral Inhalation: Pooled Results from Four Clinical Studies”, Journal of Aerosol and Pulmonary Drug Delivery, 2013,… [cited by applicant]
Kelsey Satterly et al., “Comparison of Early Plasma Exposure of DHE Following Delivery by Nasal, Oral Inhalation or Intravenous Administration”, presented at the 2019 American Headache Society Annual Meeting Jul. 11-14,… [cited by applicant]
Marttin, Emmeline et al. “Nasal Absorption of Dihydroergotamine from Liquid and Powder Formulations in Rabbits”, Journal of Pharmaceutical Sciences, 1997, vol. 86, No. 7, 802-807. [cited by applicant]
Noveck, Robert J. et al. “Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine.” Drug design, development and the… [cited by applicant]
Office Action dated Sep. 27, 2017 for U.S. Appl. No. 15/023,206. [cited by applicant]
Office action dated Jan. 30, 2017 for U.S. Appl. No. 15/023,206. [cited by applicant]
P-H. M. van der Kuy et al., “Bioavailability of intranasal formulations of dihydroergotamine”, Eur J Clin Pharmacol, 1999, 55:677-680. [cited by applicant]
Price, et al. Multiple Path Particle Dosimetry model (MPPD v1.0): A model for human and rat airway particle dosimetry. RIVM Report 650010030. Published Dec. 11, 2002. [cited by applicant]
Robert O. Cook, PhD et al., “Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential Mechanism”, Headache, 2009:49, 1423-1434. [cited by applicant]
S. Mellander and I. Nordenfelt, “Comparative Effects of Dihydroergotamine and Noradrenaline on Resistance Exchange and Capacitance Functions in the Peripheral Circulation”, Clinical Science, 1970, 39, 183-201. [cited by applicant]
Schran, Horst F. et al., “Bioequivalence and Safety of Subcutaneously and Intramuscularly Administered Dihydroergotamine in Healthy Volunteers”, Current Therapeutic Research, Dec. 1994; vol. 55, No. 12, 8 pages. [cited by applicant]
Shannon Storm, PhD et al., “Comparison of the Pharmacokinetics of STS101, an Intranasal Dry Powder Formulation of Dihydroergotamine, with Other Intranasal, Injectable, and Oral Inhaled DHE Formulations”, IHC-PO-362, pre… [cited by applicant]
Shrewsbury SB et al., “Safety, Tolerability and Comparative Bioavailability of a Novel Intranasal DHE Product (INP104)”, Headache, presented at the American Headache Society 60th Annual Meeting, June 28-Jul. 1, 2018, Sa… [cited by applicant]
Shrewsbury SB et al., “STOP 301: Open-label Safety and Tolerability of Chronic Intermittent Usage for 24/52 Weeks of INP104 [Nasal Dihydroergotamine Mesylate (DHE) Administered by Precision Olfactory Delivery (POD) Devi… [cited by applicant]
Sieneke Labruijere et al., “Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous”, Cephalalgia, 2015, vol. 35(2), 182-189. [cited by applicant]
Silberstein SD et al., “Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial”, Headache. Feb. 2007;47(2):170-80. [cited by applicant]
Stephen B. Shrewsbury, MB ChB, FFPM, Maha et al., “STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision… [cited by applicant]
Stephen D. Silberstein, MD et al., “Dihydroergotamine (DHE)—Then and Now: A Narrative Review”, Headache, 2019, 1-18. [cited by applicant]
U.S. Appl. No. 15/023,206 Office Action dated Apr. 24, 2018. [cited by applicant]
U.S. Appl. No. 15/023,206 Office Action dated Jan. 30, 2017. [cited by applicant]
U.S. Appl. No. 15/023,206 Non-Final Office Action date Aug. 27, 2019. [cited by applicant]
U.S. Appl. No. 16/414,350 Final Office Action dated Dec. 2, 2019. [cited by applicant]
U.S. Appl. No. 16/414,350 Non-Final Office Action dated Jul. 10, 2019. [cited by applicant]
W. H. Aellig, “Investigation of the Venoconstrictor Effect of 8′ Hydroxydihydroergotamine, the Main Metabolite of Dihydroergotamine, in Man”, European Journal of Clinical Pharmacology, 1984, 26:239-242. [cited by applicant]
Whyte, MD, Chad A., “Dihydroergotamine and its Use in Migraine With Posterior Fossa Symptoms”, Headache, 2010:50, 1419-1423. [cited by applicant]
Wurm, M. et al., “Comparative Trial of the Peripheral Vascular Effects of Dihydroergotamine Administered via the Intranasal and Intramuscular Routes”, Institut de Recherches Cardiovasculaires ROYAT, Sandoz Laboratories,… [cited by applicant]
Co-pending U.S. Appl. No. 17/834,583, inventors Haruta; Shunji et al., filed on Jun. 7, 2022. [cited by applicant]
Elbrond et al., Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of N N2211, a Long-Acting Glucagon Like Peptide 1 Derivative, in Healthy Male Subjects, Diabetes care, vol. 25, No. 8, Aug. 2… [cited by applicant]
EP21205407.6 Extended Search Report dated May 11, 2022. [cited by applicant]
European search report and opinion dated Aug. 17, 2022 for EP Application No. 19894836.6. [cited by applicant]
Ilium, Nasal drug delivery: New developments and strategies, research focus, DDT vol. 7, No. 23, Dec. 2002. [cited by applicant]
Jaipal, A. et al., Effect of HPMC and mannitol on drug release and bioadhesion behavior of buccal discs of buspirone hydrochloride: In-vitro and in-vivo pharmacokinetic studies, Saudi Pharmaceutical Journal (2015) 23, 3… [cited by applicant]
Le. Merck Manuals Professional Edition. Overview of Pharmacokinetics. Obtained online Sep. 2020. [cited by applicant]
Marttin, et al. Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits. J Pharm Sci. Jul. 1997;86(7):802-7. [cited by applicant]
Migranal® US Food and Drug Administration, Summary Basis of Approval, 1997. [cited by applicant]
Notice of Allowance dated Jul. 17, 2020 for U.S. Appl. No. 16/710,538. [cited by applicant]
Office action dated Apr. 23, 2020 for U.S. Appl. No. 16/710,538. [cited by applicant]
Olorunsola, Emmanuel O. et al., Evaluation of Chitosan-Microcrystalline Cellulose Blends as Direct Compression Excipients, Hindawi, Journal of Drug Delivery (2017) Article ID 8563858, 8 pages, https:ildoi.orgi10.1155/20… [cited by applicant]
Shah et al. The role of fluorine in medicinal chemistry. Journal of Enzyme Inhibition and Medicinal Chemistry 22(5):527-540 (Oct. 2007). [cited by applicant]
U.S. Appl. No. 15/023,206 Final Office Action date Feb. 12, 2020. [cited by applicant]
U.S. Appl. No. 15/023,206 Office Action dated Dec. 19, 2018. [cited by applicant]
U.S. Appl. No. 15/023,206 Office Action dated Oct. 1, 2020. [cited by applicant]
U.S. Appl. No. 16/414,350 Office Action date Apr. 19, 2021. [cited by applicant]
U.S. Appl. No. 16/414,350 Office Action date Aug. 31, 2020. [cited by applicant]
U.S. Appl. No. 16/414,350 Office Action dated Dec. 7, 2021. [cited by applicant]
U.S. Appl. No. 16/791,431 Non-Final Office Action dated Mar. 2, 2021. [cited by applicant]
U.S. Appl. No. 16/791,431 Office Action date Aug. 27, 2020. [cited by applicant]
U.S. Appl. No. 16/791,431 Office Action dated Jun. 15, 2020. [cited by applicant]
Van der Kuy et al., “Bioavailability of intranasal formulations of dihydroergotamine”, Eur J Clin Pharmacol, 1999, 55:677-680. [cited by applicant]
Vehovec, Tanja et al., Influence of different types of commercially available microcrystalline cellulose on degradation of perindopril erbumine and enalapril maleate in binary mixtures, Acta Pharm. 62 (2012) 515-528, DO… [cited by applicant]
U.S. Appl. No. 17/834,583 Office Action dated Mar. 28, 2023. [cited by applicant]
Migranal® Nasal Spray (dihydroergotamine mesylate, USP)—Package Insert N 20-148/ S-007 S-008. E-signed by R. Katz on Jul. 31, 2002. 23 pages. [cited by applicant]
Novartis. D.H.E. 45 (dihydroergotamine mesylate) Injection, USP—Prescribing Information; Package Insert. Signed by R. Katz Jul. 31, 2002. 37 pages. [cited by applicant]
Co-pending U.S. Appl. No. 18/479,335, inventors Haruta; Shunji et al., filed on Oct. 2, 2023. [cited by applicant]
International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia. vol. 11, 1991. pp. 1-12. [cited by applicant]
U.S. Appl. No. 15/023,206 Office Action dated Aug. 27, 2019. [cited by applicant]
U.S. Appl. No. 16/791,431 Office Action dated Apr. 13, 2020. [cited by applicant]
U.S. Appl. No. 17/834,583 Office Action dated Dec. 14, 2023. [cited by applicant]
U.S. Appl. No. 18/479,335 Office Action dated Jan. 24, 2024. [cited by applicant]